1. Gemenetzi, M., De Salvo, G. & Lotery, A. J. Central serous chorioretinopathy: An update on pathogenesis and treatment. Eye 24,
1743–1756. https://doi.org/10.1038/eye.2010.130 (2010).
2. van Rijssen, T. J. et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog. Retin. Eye Res. 73,
100770. https://doi.org/10.1016/j.preteyeres.2019.07.003 (2019).
3. Wang, M. et al. Central serous chorioretinopathy. Acta Ophthalmol. 86, 126–145. https://d
oi.o
rg/1 0.1 111/j.1 600-0 420.2 007.0 0889.x
(2008).
4. Matušková, V., Vysloužilová, D. & Uher, M. Half-fluence photodynamic therapy for chronic central serous chorioretinopathy:
Predisposing factors for visual acuity outcomes. Semin. Ophthalmol. 33, 690–699. https://doi.org/10.1080/08820538.2017.14164
14 (2018).
5. Stewart, J. M. Half dose verteporfin PDT for central serous chorioretinopathy. Br. J. Ophthalmol. 90, 805–806. https://doi.org/10.
1136/bjo.2006.093328 (2006).
6. Tsai, M. J. & Hsieh, Y. T. Half-time photodynamic therapy for central serous chorioretinopathy. Optom. Vis. Sci. 91, 1140–1145.
https://doi.org/10.1097/OPX.0000000000000360 (2014).
7. Hayashida, M., Miki, A., Honda, S. & Nakamura, M. Comparison between the outcomes of fluorescein angiography-guided and
indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Photodiagnosis
Photodyn. Ther. 31, 101955. https://doi.org/10.1016/j.pdpdt.2020.101955 (2020).
8. Hayashida, M. et al. Genetic factors associated with treatment response to reduced- fluence photodynamic therapy for chronic
central serous chorioretinopathy. Mol. Vis. 26, 505–509 (2020).
9. Chubachi, A. et al. Clinical factors associated with low-contrast visual acuity after reduced-fluence photodynamic therapy in
patients with resolved central serous chorioretinopathy and good baseline visual acuity. Pharmaceuticals 14, 303. https://doi.org/
10.3390/ph14040303 (2021).
10. Hayashida, M. et al. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central
serous chorioretinopathy with good baseline visual acuity. PLoS ONE 15, e0240557. https://doi.org/10.1371/journal.pone.02405
57 (2020).
11. Katsumi, O., Miyajima, H., Ogawa, T. & Hirose, T. Aniseikonia and stereoacuity in pseudophakic patients. Unilateral and bilateral
cases. Ophthalmology 99, 1270–1277. https://doi.org/10.1016/s0161-6420(92)31813-5 (1992).
12. Katsumi, O. et al. Binocular function in unilateral aphakia. CORRELATION WITH ANISEIKONIA AND STEREOACUITY.
Ophthalmology 95, 1088–1093. https://doi.org/10.1016/s0161-6420(88)33056-3 (1988).
13. Benegas, N. M., Egbert, J., Engel, W. K. & Kushner, B. J. Diplopia secondary to aniseikonia associated with macular disease. Arch.
Ophthalmol. 117, 896–899. https://doi.org/10.1001/archopht.117.7.896 (1999).
14. Ugarte, M. & Williamson, T. H. Aniseikonia associated with epiretinal membranes. Br. J. Ophthalmol. 89, 1576–1580. https://doi.
org/10.1136/bjo.2005.077164 (2005).
15. Sjöstrand, J. & Anderson, C. Micropsia and metamorphopsia in the re-attached macula following retinal detachment. Acta Ophthalmol. 64, 425–432. https://doi.org/10.1111/j.1755-3768.1986.tb06947.x (1986).
16. Hisada, H. & Awaya, S. Aniseikonia of central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 96, 369–374 (1992).
17. Rutstein, R. P. Retinally induced aniseikonia: A case series. Optom. Vis. Sci. 89, e50–e55. https://doi.org/10.1097/OPX.0b013e3182
6c5e06 (2012).
18. Gass, J. D. Pathogenesis of disciform detachment of the neuroepithelium. Am. J. Ophthalmol. https://d
oi.o
rg/1 0.1 016/0 002-9 394(67)
90026-8 (1967).
19. Spaide, R. F. et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16, 203–213
(1996).
20. Mutlak, J. A. & Dutton, G. N. Fluorescein angiographic features of acute central serous retinopathy. Acta Ophthalmol. 67, 467–469.
https://doi.org/10.1111/j.1755-3768.1989.tb01634.x (1989).
21. Yu, J. et al. The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy. BMC Ophthalmol. 19, 84. https://doi.org/10.1186/s12886-019-1089-y
(2019).
22. Ojima, Y. et al. Restoration of outer segments of foveal photoreceptors after resolution of central serous chorioretinopathy. Jpn. J.
Ophthalmol. 54, 55–60. https://doi.org/10.1007/s10384-009-0766-4 (2010).
23. Okamoto, F. et al. Aniseikonia and foveal microstructure after retinal detachment surgery. Investig. Ophthalmol. Vis. Sci. 55,
4880–4885. https://doi.org/10.1167/iovs.14-14618 (2014).
24. Shiragami, C. et al. Unintentional displacement of the retina after standard vitrectomy for rhegmatogenous retinal detachment.
Ophthalmology 117, 86-92.e1-e81. https://doi.org/10.1016/j.ophtha.2009.06.025 (2010).
25. Oh, B. L. & Yu, H. G. Choroidal thickness after full-fluence and half-fluence photodynamic therapy in chronic central serous
chorioretinopathy. Retina. 35, 1555–1560. https://doi.org/10.1097/IAE.0000000000000511 (2015).
26. Shin, J. Y., Woo, S. J., Yu, H. G. & Park, K. H. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic
therapy for chronic central serous chorioretinopathy. Retina 31, 119–126. https://doi.org/10.1097/IAE.0b013e3181e378f2 (2011).
27. Matsumoto, H., Sato, T. & Kishi, S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous
chorioretinopathy. Am. J. Ophthalmol. 148, 105-10.e1-e101. https://doi.org/10.1016/j.ajo.2009.01.018 (2009).
Acknowledgements
We gratefully acknowledge the work of past and present members of the Kobe University Department of
Ophthalmology.
Author contributions
A.M., M.H.H., and A.C.K. designed the study. A.M., M.H.H., and A.C.K. prepared the manuscript. M.O, M.K.K.,
M.H.H., and A.C.K. collected clinical data. M.H.H. and A.C.K. performed statistical analysis. W.M., H.I., S.K.,
and M.N. supervised the research. All authors reviewed and agreed with the manuscript.
Scientific Reports |
Vol:.(1234567890)
(2023) 13:17133 |
https://doi.org/10.1038/s41598-023-44415-w
www.nature.com/scientificreports/
Competing interests The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to A.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2023
Scientific Reports |
(2023) 13:17133 |
https://doi.org/10.1038/s41598-023-44415-w
Vol.:(0123456789)
...
論文の公開元へ
